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Introduction: Fetal bovine serum (FBS) is an animal product used as a medium supplement. The animal origin of FBS
is a concern if cultured stem cells are to be utilized for human cell therapy. Therefore, a substitute for FBS is desirable.
In this study, an industrial, xeno-free, pharmaceutical-grade supplement for cell culture (SCC) under development at
Grifols was tested for growth of human mesenchymal stem cells (hMSCs), cell characterization, and differentiation
capacity.
Methods: SCC is a freeze-dried product obtained through cold-ethanol fractionation of industrial human plasma pools
from healthy donors. Bone marrow-derived hMSC cell lines were obtained from two commercial suppliers. Cell growth was
evaluated by culturing hMSCs with commercial media or media supplemented with SCC or FBS. Cell viability and cell yield
were assessed with an automated cell counter. Cell surface markers were studied by indirect immunofluorescence assay.
Cells were cultured then differentiated into adipocytes, chondrocytes, osteoblasts, and neurons, as assessed by specific
staining and microscopy observation.
Results: SCC supported the growth of commercial hMSCs. Starting from the same number of seeded cells in two
consecutive passages of culture with medium supplemented with SCC, hMSC yield and cell population doubling time
were equivalent to the values obtained with the commercial medium and was consistent among lots. The viability of
hMSCs was higher than 90%, while maintaining the characteristic phenotype of undifferentiated hMSCs (positive for CD29,
CD44, CD90, CD105, CD146, CD166 and Stro-1; negative for CD14 and CD19). Cultured hMSCs maintained the potential for
differentiation into adipocytes, chondrocytes, osteoblasts, and neurons.
Conclusions: The tested human plasma-derived SCC sustains the adequate growth of hMSCs, while preserving their
differentiation capacity. SCC can be a potential candidate for cell culture supplement in advanced cell therapies.Introduction
Human mesenchymal stem cells (hMSCs) are multipotent
cells with the capacity to differentiate into multiple types of
functionally mature lineage-specific cells [1,2]. In addition,
hMSCs have a low immunogenicity – which can help to
improve allogenic transplantation and avoid immune rejec-
tion, one of the main complications of stem cell use in cell
therapy [3-8]. These characteristics make hMSCs of great
interest for use in regenerative medicine therapies, as well* Correspondence: josemaria.diez@grifols.com
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unless otherwise stated.as a treatment for many diseases [9]. The infusion of
hMSCs has been positively tested in preclinic acute lung in-
juries, myocardium stroke, diabetes, and multiple sclerosis,
as well as hepatic and renal failure, among other areas
[10,11].
Representing the majority of the adherent fraction of
the bone marrow, hMSCs are 0.001 to 0.01% of the whole
marrow and can be isolated easily from different tissues
[12]. Although in vivo sources provide very small quan-
tities of hMSCs, these cells can be expanded by culture
in vitro. However, the need for a stable, standard, and safe
in vitro culture medium is one of the major shortcomings
of hMSC use in advanced therapies.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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with fetal bovine serum (FBS), which provides growth fac-
tors, adhesion factors, and vital nutrients essential for the
culture of this type of cell [13,14]. The use of FBS (or
nonxeno-free supplements) is appropriate for in vitro re-
search but, due to its animal origin, could be a concern if
the cultured cells are used for human cell therapy [15-17].
Furthermore, the use of xenogeneic sera has high lot-to-
lot variability and is associated with potential patient im-
mune reactions [18]. Therefore, for the translation of stem
cells to clinical uses, it is ideal to perform the culture
under xeno-free conditions [16].
A number of studies have tested alternative cell culture
serum supplements from various human origins to deter-
mine a better substitute for FBS [15,16,19-21]. There is
consensus that the use of human-derived serum supple-
ments is the preferred alternative in cell cultures intended
for cell-based therapy. However, blood bank products have
small pool sizes that could provide less consistency than
products from a larger, industrial plasma pool.
In an effort to overcome these shortcomings, a new in-
dustrial, good manufacturing practice -produced, xeno-free,
pharmaceutical-grade, human plasma-derived supplement
for cell culture (SCC) is under development at Grifols
(Parets del Vallès, Barcelona, Spain). SCC has been success-
fully used for the culture of human embryonic stem cells,
for the culture of induced pluripotent stem cells, for the re-
programming of human fibroblasts to induced pluripotent
stem cells [22], and for the culture of other mammalian cell
lines [23]. In the present study, SCC was tested to deter-
mine its ability to support cell growth of hMSCs in vitro. In
addition, characterization and viability of hMSCs cultured
in SCC-containing media as well as hMSC capacity to dif-
ferentiate into neural precursors were assessed.
Methods
Production of the human cell culture supplement
SCC is a freeze-dried preparation manufactured under good
manufacturing practice rules and is obtained from human
plasma through cold-ethanol industrial fractionation [24].
Plasma used for SCC production is collected from healthy
donors after signing the consent agreement for automatic
plasmapheresis at US Food and Drug Administration-
licensed plasmapheresis centers of the Grifols network
(Biomat, USA), where plasma is specifically collected for use
as the starting material in the industrial production of
plasma-derived therapeutic products. Fractionation
plasma pools contain donations from over 1,000 differ-
ent donors. Each individual donation is serologically
tested for transfusion-transmissible viral markers, and
all plasma is tested using nucleic acid techniques for the
presence of DNA or RNA from human immunodefi-
ciency virus, hepatitis A virus, hepatitis B virus, hepatitis
C virus, and human parvovirus B19. Moreover, SCC hasa specific viral inactivation step (gamma irradiation) in-
corporated into the production process in addition to
purification steps with pathogen removal capacity.
Owing to manufacturing conditions, SCC biological
properties are consistent from lot to lot.
For the experiments described in this study, if not stated
otherwise, SCC was reconstituted with Basal Medium 2
(BM2), a culture medium developed at Grifols. The BM2
formulation is based on Dulbecco’s modification of Eagle’s
medium and Ham’s F12 (Gibco-Life Technologies, Carlsbad,
CA, USA) with commonly employed growth factors (such
as basic fibroblast growth factor plus the growth factors
from platelet lysates) and other elements added (such as in-
sulin, sodium selenite, and ethanolamine). This medium can
be used in combination with SCC and FBS.
Human mesenchymal stem cell culture
Two hMSC cell lines obtained from the bone marrow of
healthy donors, provided by two different commercial
suppliers – PT-2501 from a 21-year-old female and a 22-
year-old female (Lonza Group Ltd, Basel, Switzerland), and
C-12974 from a 64-year-old male (PromoCell GmbH,
Heidelberg, Germany) – were used in this study. Because
these cells are commercially available, no patient consent or
approval from Ethics Committee was needed.
Cells were cultured at 37°C and 8% carbon dioxide with
the media recommended by the manufacturer. The media
were changed every other day and the cells were split enzy-
matically with Trypsin: 1× phosphate-buffered saline (Ref.
14190–185; Gibco Life Technologies) and Tryple Express
(Ref. 12604–013; Gibco-Life Technologies) for PT-2501
cells, and the Trypsin kit (PromoCell GmbH) for C-12974
cells. Cultures were trypsinized when the cells were approxi-
mately 90% confluent.
Human mesenchymal stem cell growth evaluation
Cell growth of hMSCs was qualitatively evaluated by mi-
croscopy and classified as positive (+) for positive growth
to reach 90% confluence and negative (−) for no growth
(<400 cells/cm2) in five different media formulations: BM2
without supplementation, BM2 with FBS 10% (mesenchy-
mal stem cell qualified; Gibco-Life Technologies), BM2
containing SCC up to 40% v/v, and media from each of
the two hMSC suppliers (Lonza Group and PromoCell).
The same commercial cells were also grown in a classical
medium (Dulbecco’s Modification of Eagle’s Medium and
Ham’s F12) supplemented with FBS.
For the determination of the working SCC concentra-
tion required for the optimal hMSC growth in BM2, SCC
concentrations from 0 to 40% v/v were tested. The extent
of cell proliferation was determined by a tetrazolium-
based colorimetric assay for cell chemosensitivity that de-
tects metabolically active cells [25]. The Cell Proliferation
Assay kit (Merck Millipore, Billerica, MA, USA) was used,
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prepared media were filtered through 0.45 μm and
0.22 μm pore filters (Merck Millipore); cells were trypsi-
nized, resuspended in their medium, and seeded at a con-
centration of 5,000 cells/cm2 in plates and flasks (Corning
Inc. Life Sciences, Tewksbury, MA, USA). Cells were incu-
bated at 37°C and 5% carbon dioxide without changing
the media. After 5 days incubation, 20 μl WST-1/ECS re-
agent (Ref. 2210; Merck Millipore) was added. After a sub-
sequent 4 hours of incubation, absorbance at 450 nm was
read.
Human mesenchymal stem cell culturing assessments
Studies on hMSC yield, replicative capacity, and cell viabil-
ity were performed with the commercial hMSC lines in
two consecutive culture passages from seeding (passages 1
and 2; inoculum with a fixed cell count at day 0) after 7 to
10 days in culture. Cultured cells in commercial medium
and medium containing SCC at the determined working
concentration for optimal hMSC growth were compared
(Student’s t test in three experiments each; mean ± standard
deviation).
Cell yield was assessed by microscopy and cell count.
When hMSCs reached 90% confluence, cells were trypsi-
nized. A cell count was then performed by an automated
cell counter (Countess™; Invitrogen-Life Technologies,
Carlsbad, CA, USA). The result was expressed as the
number of cells per square centimeter of cell culture
surface (cells/cm2). Cell viability was assessed after trypsi-
nization of the culture flask using trypan blue staining
(Life Technologies, Carlsbad, CA, USA). The number of
viable cells in relation to the total cell count was calcu-
lated [25].
Cell replicative capacity was evaluated by the population
doubling time (PDT) [26]. The hMSCs at a density of 5,000
cells/cm2 were seeded and cultured as described. Cell num-
bers were calculated with the following formula [27]:
PDT ¼ 1 = 3:32 log NH– log N1ð Þ = t2– t1ð Þ½ 
where NH is the number of harvested cells at the end of
the growth period, N1 is the number of seeded cells, t1 is
the time at seeding, and t2 is the time elapsed between
t1 and cell harvesting.
Characterization of hMSC cell surface markers
Immunofluorescence staining was used to qualitatively
determine cell surface markers in the hMSC lines cultured
in medium containing SCC (at the determined working
concentration for optimal hMSC growth). Seven positive
markers – CD29 (Ref. 303002; Biolegend, San Diego, CA,
USA), CD44 (Ref. CBL154; Merck Millipore ), CD90 (Ref.
CBL1500F; Merck Millipore), CD105 (Ref. MABT117;
Merck Millipore), CD146 (Ref. EPR3208; Merck Millipore),CD166 (Ref. 343902; Biolegend), and Stro-1 (Ref.
MAB4315; Merck Millipore) – and two negative markers –
CD14 (Ref. MAB1794; Merck Millipore) and CD19 (Ref.
MAB1794; Merck Millipore) – for hMSCs were studied
[12,28-33]. These markers were also studied for cells cul-
tured with commercial media (data not shown).
When the hMSCs were at day 6 and at day 7 of cul-
ture, a plate was seeded with 1.9 × 104 cell/ml and incu-
bated for 3 days at 37°C and 5% carbon dioxide.
The cells were fixed with 4% paraformaldehyde (Ref.
FB001; Invitrogen-Life Technologies) at room temperature
for 40 minutes, followed by overnight incubation with a
blocking solution. Fixed cells were then incubated over-
night at 4°C with the primary antibodies (diluted 1:100 in
blocking buffer) against the markers. Afterwards, the sam-
ple was washed with phosphate-buffered saline containing
blocking buffer and incubated with secondary antibodies
(diluted 1:100 in blocking buffer), donkey anti-mouse IgG
conjugated with fluorescein isothiocyanate (Ref. AP192F;
Merck Millipore), and goat anti-mouse IgM conjugated
with Cy3 (Ref. AP128C; Merck Millipore). Finally, the
sample was counterstained with 4',6-diamidino-2-pheny-
lindole (Ref. D3571; Invitrogen-Life Technologies) and vi-
sualized under the fluorescence microscope (Axiobserver




The hMSCs were cultured in commercial medium or one
of two laboratory-made media formulations supplemented
with SCC – each containing additional platelet lysate. After
reaching 90% confluence, the cells were harvested and
reseeded into a 24-well plate (6 × 104 cells/well) for adipo-
genic differentiation. Commercial differentiation medium
(Ref. C-28011; PromoCell) was used to induce adipogenesis.
After 14 days, differentiation was assessed by observation
of cell morphology and the specific staining of lipid droplets
with Oil Red O (Ref. O0625-25G; Sigma-Aldrich, St. Louis,
MO, USA).
Osteogenic differentiation
Similarly, the hMSCs were cultured in commercial medium
or one of two laboratory-made media formulations supple-
mented with SCC. After reaching 90% confluence, the cells
were harvested and reseeded into a 24-well plate (6 × 104
cells/well) for osteogenic differentiation. The hMSCs were
differentiated into osteoblasts using a commercial differen-
tiation medium (Ref. C-28013; PromoCell). After 21 days of
incubation, differentiation was assessed by observation of
cell morphology changes and by the specific staining of
extracellular calcium deposits with Alizarin Red S (Ref.
A5533-25G; Sigma-Aldrich). Moreover, alkaline phosphat-
ase activity was measured with the use of the combination
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3’-indolyl phosphate p-toluidine salt and nitro-blue tetrazo-
lium chloride (BCIP/NBT tablet, Ref. B5655-5TAB; Sigma-
Aldrich).Figure 1 Human mesenchymal stem cell proliferation in Basal
Medium 2 culture medium containing supplement for cell culture.
Proliferation was determined by colorimetric assay (absorbance atChondrogenic differentiation
The hMSCs were cultured in commercial medium or one
of two laboratory-made media formulations supplemented
with SCC. After reaching 90% confluence, the cells were
harvested and reseeded in 15 ml conical tubes at 2.5 × 105
cells/tube. Mesenchymal stem cell (MSC) spheroids formed
in the tubes and were incubated with commercial MSC
chondrogenic differentiation medium (Ref. C-28012; Pro-
moCell). After 21 days of culture, the cells were stained
with Alcian Blue (Ref. A3157-10G; Sigma-Aldrich) to deter-
mine differentiation.450 nm) for cell chemosensitivity to detect metabolically active cells.
Concentrations of supplement for cell culture (SCC) ranged from 0 to
40% v/v. O.D., optical density.Neurogenic differentiation
Neurogenic cell differentiation studies were also performed
with the commercial hMSC lines. Cultured cells in commer-
cial medium and in BM2+ SCC medium (at the determined
optimal concentration for hMSC growth) were morpho-
logically compared. Plates were covered with 10 μg/ml fibro-
nectin (Ref. C-43050; PromoCell) in 1× phosphate-buffered
saline and left to dry. The hMSCs were seeded at a concen-
tration of 4,000 cells/cm2 and cultured until cells were
approximately 50 to 90% confluent. Then, hMSC neurogen-
esis was induced by switching the medium to a commercial
differentiation medium (Ref. C-28015; PromoCell). Differen-
tiation and cell morphology (acquisition of mature axonal/
dendritic polarity) was assessed by the specific staining of
Nissl bodies [34] and microscopy [35].Table 1 Cell growth of the human mesenchymal stem
cells cultured in different media formulations and
supplements
hMSC line Medium Supplement Growth












BM2, Basal Medium 2; DMEM/F12, Dulbecco’s Modification of Eagle’s Medium
and Ham’s F12; FBS, fetal bovine serum; hMSC, human mesenchymal stem cell;
SCC, supplement for cell culture.Results
Cell growth
The hMSCs grew to confluence with both the commercial
media and the BM2 medium supplemented with SCC or
FBS (Table 1). The BM2 medium without supplementa-
tion did not promote cell growth. The cells also did not
grow when Dulbecco’s Modification of Eagle’s Medium
and Ham’s F12 supplemented with FBS only was used.
Results of the studies to determine the SCC concentra-
tion for optimal hMSC growth are shown in Figure 1. Max-
imal cell growth was observed between 10 and 20% v/v.
Therefore, 15% v/v was used as the working SCC concen-
tration for subsequent experiments.Figure 2 Human mesenchymal stem cell yield in two consecutive
culture passages. Cells were maintained for 7 to 10 days in culture with
commercial medium and with medium containing 15% supplement for
cell culture (SCC) from seeding with a fixed cell count at day 0 (inoculum)
(n= 3).
Figure 3 Surface markers. Illustrative micrographs of human mesenchymal stem cell surface markers as determined by immunofluorescence
staining in cells cultured in medium containing 15% supplement for cell culture.
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The hMSC yield in the two passages of culture with
medium containing 15% SCC was similar to the cell
yield obtained with the commercial medium (Figure 2).
Starting from the same cell seeding load (inoculum), the
average yield was 2.3-fold to 2.7-fold for passage 1 and
fourfold to fivefold for passage 2.Cell replicative capacity
The PDT was similar for both the commercial medium
and the medium containing 15% SCC. At passage 1, the
average PDT was 4.5 ± 0.7 days for the commercial
medium and 4.0 ± 1.1 days for the medium containing
15% SCC. At passage 2, the PDT was 4.2 ± 2.2 days and
5.8 ± 1.6 days for the commercial medium and the
medium containing SCC, respectively.Cell viability
Cell viability was high for both media, with averages of
95.5 ± 1.8% and 92.2 ± 6.3% (passages 1 and 2, respect-
ively) for cells cultured with the commercial medium
and 96.5 ± 3.1% and 92.2 ± 4.3% (passages 1 and 2, re-
spectively) for cells cultured with medium containing
15% SCC.Figure 4 Adipogenic differentiation. Illustrative micrographs of human
mesenchymal stem cells (hMSCs) cultured with commercial medium and
with Basal Medium 2 with 15% supplement for cell culture (SCC), showing
adipogenic differentiation. Lipid droplets (oil Red O staining) characteristic
for adipocytes can be observed.Cell surface markers
The hMSCs cultured in medium containing 15% SCC
were positive for CD29, CD44, CD90, CD105, CD146,
CD166, and Stro-1, whereas they were negative for
CD14 and CD19 (Figure 3).Adipogenic differentiation
The hMSCs cultured with SCC preserved the potential
for differentiation into adipocytes. After adipogenic
differentiation, hMSCs showed a morphology charac-
teristic for adipocytes (Figure 4). Oil Red O staining
revealed lipid droplets. In all of the cell groups, incu-
bated in either commercial basal medium or BM2 for-
mulations supplemented with SCC and platelet lysate,
differentiation was observed.
Osteogenic differentiation
The hMSCs cultured with SCC preserved the potential for
differentiation into osteogenic cells (Figure 5). After indu-
cing differentiation, the cells showed traits characteristic for
osteoblasts – cuboidal shape with flattened morphology.
Alizarin Red S staining revealed extracellular calcium
Figure 5 Osteogenic differentiation. Illustrative micrographs of human mesenchymal stem cells (hMSCs) cultured with commercial medium
and with Basal Medium 2 with 15% supplement for cell culture (SCC), showing osteogenic differentiation. Alizarin Red S staining revealed
extracellular calcium deposits. Alkaline phosphatase activity was present in the differentiated cells, which was shown by 5-bromo-4-chloro-3'-
indolyl phosphate p-toluidine salt and nitro-blue tetrazolium chloride (BCIP/NBT tablet, Ref. B5655-5TAB; Sigma-Aldrich, St. Lous, MO, USA)
staining.
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in the differentiated cells, which was shown by the BCIP/
NBT tablet staining. In all of the cell groups, incubated in
either commercial MSC basal medium or BM2 formula-
tions supplemented with SCC, differentiation was observed
at a similar level.Chondrogenic differentiation
The hMSCs cultured with SCC preserved the potential for
differentiation into cartilage (Figure 6). After inducing dif-
ferentiation, Alcian Blue staining revealed the presence of
glycosaminoglycans characteristic for the extracellular
matrix of cartilage. In all of the cell groups, incubated in
either commercial MSC basal medium or BM2 formula-
tions supplemented with SCC, differentiation was ob-
served at a similar level.Neurogenic differentiation
After neurogenic differentiation induction, microscopy
examination of hMSCs cultured with both the commercial
medium and with medium containing 15% SCC showed
neuronal morphology with elongated axons and dendrites
(Figure 7). These features were not observed in the undif-
ferentiated cells. Nissl staining showed Nissl bodies around
the nucleus in differentiated cells but not in undifferenti-
ated cells.
Discussion
The interest in hMSCs for use in cell therapy and tissue
engineering has been growing in the last two decades.
Because the use of animal sera to supplement hMSC
culture media may be problematic, several studies have
recently addressed the use of xeno-free [36-40] and
serum-free [38,40-42] culture conditions for isolation/
Figure 6 Chondrogenic differentiation. Macroscopic photograph showing human mesenchymal stem cells (hMSCs) cultured with commercial medium
and with Basal Medium 2 with 15% supplement for cell culture (SCC), brought under chondrogenic differentiation. Pellets were stained with Alcian Blue for
cartilage. Differentiated spheroids show intense blue color, while undifferentiated mesenchymal stem cells are faintly bluish or almost colorless.
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bone marrow [36,39,41,42], adipose tissue [36,38,39],
human Warton’s jelly [37], and umbilical cord matrix
[40]. In this study, we have evaluated the first xeno-free,
pharmaceutical-grade SCC derived from human plasma,
currently under development. Our study has shown that
SCC can be a viable substitute for FBS in clinical-grade,
human stem cell culture.
The tested SCC is a freeze-dried product manufactured
under good manufacturing practice, ensuring consistency
and compliance because all critical processes are clearly de-
fined, controlled, and validated. In addition, lyophilization
is convenient for transport and storage. SCC derived from
an industrial plasma pool constituted from over 1,000 hu-
man donors results in a consistent final product with little
variability between batches [43]. High lot-to-lot stability is
evidenced by the low standard deviation (below one-third
of the mean in average) observed in our studies on hMSC
yield, replicative capacity, and cell viability. SCC also pro-
vides factors, which could facilitate the improved growth ofcells under conditions more similar to those that occur
within the human body. SCC can therefore help to over-
come the problem of extensive lot-to-lot variability associ-
ated with FBS due to its complex mixture of defined and
unknown biological products [44].
Cell growth tests from this study highlight the po-
tential of SCC as media supplementation for not only
hMSC culture. As reported previously, SCC as a media
supplement can also be used for other cell types, in-
cluding human embryonic stem cells, induced pluripo-
tent stem cells, Chinese hamster ovarian cells, Vero
cells, and mouse BALB/c myeloma cells, as reported
previously [22,23]. With 15% SCC supplementation,
the hMSC yield, replicative capacity, and cell viability
were comparable with those observed with the com-
mercial medium, indicating that normal use of SCC as
a substitute for FBS can be performed reliably. A previ-
ous study has also tested cell growth and differentiation
capacity with various concentrations of autologous
serums versus FBS [45].
Figure 7 Neurogenic differentiation. Illustrative micrographs of human mesenchymal stem cells (hMSCs) cultured with commercial medium
and with Basal Medium 2 with 15% supplement for cell culture (SCC), before and after induction of neurogenic differentiation. Elongated axons
and dendrites as well as stained Nissl bodies can be observed in the differentiated cells.
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identified for hMSCs, there are a number of surface recep-
tors associated with their function, which helps to
characterize hMSCs. The International Society for Cellular
Therapy has proposed that MSCs are positive for antigens
such as CD90 (Thy-1) and CD105 (endoglin) [29], which
were detected in our studies. Additionally, these cells do
not express hematopoietic markers such as CD14 and B-
cell markers such as CD19 [29]. Consistent with these
studies, our cultured hMSCs did not express such antigens.
Other surface receptors detected in our cultured hMSCs
included CD44 and CD29 (integrin β1), which are involved
in cell–matrix interactions and have been shown to be
expressed in MSCs [28,31]. In addition, CD146 (MCAM),
CD166 (ALCAM), and Stro-1 were expressed in our cul-
tured hMSCs. These antigens can be employed as pheno-
typic markers for MSCs, although they can also be found in
other cell types [12,32,33]. Ultimately for the cell surface
markers studied, hMSCs cultured with SCC-supplementedmedium showed the cell phenotype expected for undiffer-
entiated hMSCs, at least for the first two culture passages.
Currently, similar results have been obtained in preliminary
studies performed in our laboratory in which hMSCs from
other origins exhibit similar growth and cell surface marker
expression (data not shown).
The capacity of the cultured hMSCs to maintain
their multipotent state to further differentiate into
other cells types is a key issue for clinical therapies.
According to Dominici and colleagues, the minimal
criteria for hMSC to be defined as such are that the
cells have to be able to differentiate into osteogenic,
adipogenic, and chondrogenic cell lines [29]. The
hMSCs cultured in the medium supplemented with
SCC maintained the capacity to differentiate into adi-
pocytes, osteoblasts, and chondrocytes, indicating that
their multipotent potential is preserved by SCC supple-
mentation. This is particularly important, as hMSC dif-
ferentiation potential is crucial for implementation in
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cine therapies.
Since the central nervous system has limited capacity of
regenerating lost neurons, transplantation of pluripotent
stem cells or stem cell-derived progenitors is seen as a
promising therapeutic strategy to repair the damaged tis-
sue in neurological conditions such as Parkinson’s disease,
Alzheimer’s disease, Huntington’s disease, stroke, or spinal
cord injury [46]. The differentiation of cultured hMSCs
into cells of neuronal lineages can be monitored through
follow-up of changes in cell morphology such as the forma-
tion of dendrites and axons [35]. Alternatively, structures
specific to the soma of neurons such as Nissl bodies can be
detected immunohistochemically [34]. In our study, these
features were observed in hMSCs after neurogenic differen-
tiation induction. Therefore, hMSCs cultured with com-
mercial medium or SCC-supplemented medium preserved
the potential for differentiation into neurons.
The use of commercial hMSCs instead of cells isolated
directly from donors is a limitation of the study when
considering clinical implications. In addition, evalua-
tions were mostly qualitative and were performed in a
limited number of culture passages. To confirm SCC
clinical applicability, further investigations such as
genotyping assessments are advisable.
Conclusions
Grifols’ human plasma-derived SCC is a safe and stable
xeno-free, pharmaceutical-grade supplement that sustains
the growth of hMSCs. The hMSCs cultured with SCC are
able to later differentiate into a specific cell type. These fea-
tures make this human plasma-derived SCC a potential can-
didate for cell culture supplementation in advanced cell
therapies designated for regenerative medicine applications.
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